Maree T Smith

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8273388/publications.pdf

Version: 2024-02-01

174	7,577	53660	62479
papers	citations	45 h-index	80 g-index

176	176	176	7656
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources. Journal of Medicinal Chemistry, 2022, 65, 1612-1661.	2.9	13
2	Journey to the Market: The Evolution of Biodegradable Drug Delivery Systems. Applied Sciences (Switzerland), 2022, 12, 935.	1.3	16
3	Design, synthesis and evaluation of alpha lipoic acid derivatives to treat multiple sclerosis-associated central neuropathic pain. Bioorganic and Medicinal Chemistry, 2022, 69, 116889.	1.4	3
4	Characterisation of a rat model of mechanical low back pain at an advanced stage using immunohistochemical methods. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 96-106.	0.9	1
5	Sustained release ketamine-loaded porous silicon-PLGA microparticles prepared by an optimized supercritical CO2 process. Drug Delivery and Translational Research, 2021, , 1.	3.0	3
6	Assessment of the Anti-Allodynic and Anti-Hyperalgesic Efficacy of a Glycine Transporter 2 Inhibitor Relative to Pregabalin, Duloxetine and Indomethacin in a Rat Model of Cisplatin-Induced Peripheral Neuropathy. Biomolecules, 2021, 11, 940.	1.8	5
7	Pharmacological characterization of the chronic phase of the monoiodoacetateâ€induced rat model of osteoarthritis pain in the knee joint. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1515-1522.	0.9	5
8	Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. Pharmaceutics, 2021, 13, 1505.	2.0	3
9	Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Delivery and Translational Research, 2021, , 1.	3.0	0
10	Use of Microfluidics to Fabricate Bioerodable Lipid Hybrid Nanoparticles Containing Hydromorphone or Ketamine for the Relief of Intractable Pain. Pharmaceutical Research, 2020, 37, 211.	1.7	9
11	Assessment of the antiâ€hyperalgesic efficacy of Jâ€2156, relative to clinically available analgesic/adjuvant agents in a rat model of mild to moderate chronic mechanical low back pain (LBP). Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1912-1922.	0.9	1
12	Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain. Pharmacological Reports, 2020, 72, 1418-1425.	1.5	5
13	Comparative studies of glial fibrillary acidic protein and brainâ€derived neurotrophic factor expression in two transgenic mouse models of Alzheimerâ€™s disease. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1740-1750.	0.9	0
14	In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the Î²-arrestin2 recruitment assay: No two ligands have the same profile. European Journal of Pharmacology, 2020, 872, 172947.	1.7	8
15	Intracerebroventricular administration of CYX-6, a potent Î¼-opioid receptor agonist, a Î´- and Îº-opioid receptor antagonist and a biased ligand at Î¼, Î´ & Îº-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine. European Journal of Pharmacology, 2020, 871, 172918.	1.7	12
16	Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. International Journal of Pharmaceutics, 2020, 581, 119291.	2.6	36
17	Countering opioid-induced respiratory depression by non-opioids that are respiratory stimulants. F1000Research, 2020, 9, 91.	0.8	24
18	Transcriptomic characterisation of the optimised rat model of Walker 256 breast cancer cellâ€induced bone pain. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 1201-1215.	0.9	2

#	Article	IF	Citations
19	Cyclooctatetraene: A Bioactive Cubane Paradigm Complement. Chemistry - A European Journal, 2019, 25, 2729-2734.	1.7	24
20	Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy. Methods and Protocols, 2019, 2, 38.	0.9	0
21	The cubane paradigm in bioactive molecule discovery: further scope, limitations and the cyclooctatetraene complement. Organic and Biomolecular Chemistry, 2019, 17, 6790-6798.	1.5	49
22	J-2156, a somatostatin receptor type 4 agonist, alleviates mechanical hyperalgesia in a rat model of chronic low back pain. Biomedicine and Pharmacotherapy, 2019, 117, 109056.	2.5	8
23	Bioerodable Ketamine-Loaded Microparticles Fabricated Using Dissolvable Hydrogel Template Technology. Journal of Pharmaceutical Sciences, 2019, 108, 1220-1226.	1.6	7
24	Nitric oxide modulates Î¼â€opioid receptor function in vitro. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 676-685.	0.9	5
25	Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls. ACS Chemical Neuroscience, 2019, 10, 201-208.	1.7	8
26	Establishment and characterisation of a stavudine (d4T)-induced rat model of antiretroviral toxic neuropathy (ATN) using behavioural and pharmacological methods. Inflammopharmacology, 2019, 27, 387-396.	1.9	2
27	Sustained-Release Hydromorphone Microparticles Produced by Supercritical Fluid Polymer Encapsulation. Journal of Pharmaceutical Sciences, 2019, 108, 811-814.	1.6	13
28	Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology, 2018, 131, 238-255.	2.0	97
29	Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy. Drug Metabolism Reviews, 2018, 50, 109-124.	1.5	2
30	Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology, 2018, 26, 77-86.	1.9	62
31	Morphine hyposensitivity in streptozotocinâ€diabetic rats: Reversal by dietary <scp>l</scp>â€arginine treatment. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 42-49.	0.9	6
32	An improved liquid chromatography tandem mass spectrometry (LCâ€“MS/MS) method for quantification of dexmedetomidine concentrations in samples of human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1073, 118-122.	1.2	6
33	Inhibition of acidâ€sensing ion channels by diminazene and APETx2 evoke partial and highly variable antihyperalgesia in a rat model of inflammatory pain. British Journal of Pharmacology, 2018, 175, 2204-2218.	2.7	39
34	Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: a cross-sectional pilot study. Pain Reports, 2018, 3, e669.	1.4	26
35	Formulation of Bioerodible Ketamine Microparticles as an Analgesic Adjuvant Treatment Produced by Supercritical Fluid Polymer Encapsulation. Pharmaceutics, 2018, 10, 264.	2.0	8
36	An improved LCâ€“MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity. Bioanalysis, 2018, 10, 1577-1590.	0.6	5

#	Article	IF	Citations
37	In vivo profiling of four centrally administered opioids for antinociception, constipation and respiratory depression: Betweenâ€colony differences in Sprague Dawley rats. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1056-1066.	0.9	5
38	Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatinâ€induced peripheral neuropathy. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 1067-1075.	0.9	8
39	Chronic low back pain: a mini-review on pharmacological management and pathophysiological insights from clinical and pre-clinical data. Inflammopharmacology, 2018, 26, 881-898.	1.9	19
40	The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain. Frontiers in Pharmacology, 2018, 9, 495.	1.6	17
41	Optimization and In Vivo Profiling of a Refined Rat Model of Walker 256 Breast Cancer Cell-Induced Bone Pain Using Behavioral, Radiological, Histological, Immunohistochemical and Pharmacological Methods. Frontiers in Pharmacology, 2017, 8, 442.	1.6	15
42	Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. Frontiers in Pharmacology, 2017, 8, 493.	1.6	14
43	Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia â€“ A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. Frontiers in Molecular Neuroscience, 2017, 10, 389.	1.4	16
44	Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience, 2016, 10, 88.	1.0	27
45	Evaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of Chemicals. Frontiers in Pharmacology, 2016, 7, 53.	1.6	10
46	Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Frontiers in Pharmacology, 2016, 7, 185.	1.6	255
47	The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats. Frontiers in Pharmacology, 2016, 7, 286.	1.6	38
48	The effect of 1Âmg folic acid supplementation on clinical outcomes in female migraine with aura patients. Journal of Headache and Pain, 2016, 17, 60.	2.5	29
49	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie, 2016, 128, 3644-3649.	1.6	34
50	Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie - International Edition, 2016, 55, 3580-3585.	7.2	126
51	Frontispiece: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie - International Edition, 2016, 55, .	7.2	1
52	Frontispiz: Validating Eaton's Hypothesis: Cubane as a Benzene Bioisostere. Angewandte Chemie, 2016, 128, .	1.6	0
53	In Vitro Metabolic Stability and in Vivo Biodistribution of 3-Methyl-4-furoxancarbaldehyde Using PET Imaging in Rats. ACS Medicinal Chemistry Letters, 2016, 7, 563-567.	1.3	11
54	High-throughput assay for quantification of the plasma concentrations of thiopental using automated solid phase extraction (SPE) directly coupled to LCâ€“MS/MS instrumentation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1038, 80-87.	1.2	6

#	Article	IF	Citations
55	Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain. Pain, 2016, 157, S33-S41.	2.0	42
56	Antiallodynic effects of alpha lipoic acid in an optimized <scp>RR</scp>â€<scp>EAE</scp> mouse model of <scp>MS</scp>â€neuropathic pain are accompanied by attenuation of upregulated <scp>BDNF</scp>â€TrkBâ€<scp>ERK</scp> signaling in the dorsal horn of the spinal cord. Pharmacology Research and Perspectives, 2015, 3, e00137.	1.1	32
57	Neurotrophins and Neuropathic Pain: Role in Pathobiology. Molecules, 2015, 20, 10657-10688.	1.7	145
58	In vivo High Angular Resolution Diffusion-Weighted Imaging of Mouse Brain at 16.4 Tesla. PLoS ONE, 2015, 10, e0130133.	1.1	32
59	In vitro methods for hazard assessment of industrial chemicals â€“ opportunities and challenges. Frontiers in Pharmacology, 2015, 6, 94.	1.6	20
60	The furoxan nitric oxide donor, <scp>PRG</scp>150, evokes doseâ€dependent analgesia in a rat model of painful diabetic neuropathy. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 921-929.	0.9	14
61	Angiotensin II Type 2â€Receptor: New Clinically Validated Target in the Treatment of Neuropathic Pain. Clinical Pharmacology and Therapeutics, 2015, 97, 128-130.	2.3	13
62	A novel fully validated LCâ€“MS/MS method for quantification of pyridoxal-5â€²-phosphate concentrations in samples of human whole blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1000, 77-83.	1.2	9
63	Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion on Therapeutic Targets, 2015, 19, 25-35.	1.5	32
64	Topical Application of a Novel Oxycodone Gel Formulation (Tocopheryl Phosphate Mixture) in a Rat Model of Peripheral Inflammatory Pain Produces Localized Pain Relief Without Significant Systemic Exposure. Journal of Pharmaceutical Sciences, 2015, 104, 2388-2396.	1.6	14
65	Novel Polymeric Bioerodable Microparticles for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain. Journal of Pharmaceutical Sciences, 2015, 104, 2334-2344.	1.6	23
66	In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. British Journal of Pharmacology, 2015, 172, 532-548.	2.7	57
67	Current developments in MRI for assessing rodent models of multiple sclerosis. Future Neurology, 2014, 9, 487-511.	0.9	1
68	Analgesic Efficacy and Mode of Action of a Selective Small Molecule Angiotensin II Type 2 Receptor Antagonist in a Rat Model of Prostate Cancer-Induced Bone Pain. Pain Medicine, 2014, 15, 93-110.	0.9	45
69	Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. Behavioural Pharmacology, 2014, 25, 732-740.	0.8	32
70	Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behavioural Pharmacology, 2014, 25, 137-146.	0.8	23
71	Endomorphin analogues with mixed Î¼-opioid (MOP) receptor agonism/Î´-opioid (DOP) receptor antagonism and lacking Î²-arrestin2 recruitment activity. Bioorganic and Medicinal Chemistry, 2014, 22, 2208-2219.	1.4	12
72	Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology, 2014, 22, 1-22.	1.9	98

#	Article	IF	Citations
73	Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 798-806.	0.9	31
74	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacology Biochemistry and Behavior, 2014, 126, 13-27.	1.3	34
75	Fully validated LCâ€“MS/MS method for quantification of homocysteine concentrations in samples of human serum: A new approach. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 972, 14-21.	1.2	21
76	Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: A mini review. Journal of Neuroscience Methods, 2014, 233, 166-171.	1.3	23
77	Peripherally acting novel lipo-endomorphin-1 peptides in neuropathic pain without producing constipation. Bioorganic and Medicinal Chemistry, 2013, 21, 1898-1904.	1.4	17
78	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology, 2013, 21, 339-363.	1.9	38
79	Comment on â€œprotective arms of the reninâ€angiotensin system in neurological diseaseâ€. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 838-838.	0.9	0
80	Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology Biochemistry and Behavior, 2013, 106, 33-46.	1.3	26
81	The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiology, 2013, 13, 7.	0.7	38
82	Small Molecule Angiotensin II Type 2 Receptor (AT₂R) Antagonists as Novel Analgesics for Neuropathic Pain: Comparative Pharmacokinetics, Radioligand Binding, and Efficacy in Rats. Pain Medicine, 2013, 14, 692-705.	0.9	79
83	A Small Molecule Angiotensin II Type 2 Receptor (AT₂R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. Pain Medicine, 2013, 14, 1557-1568.	0.9	66
84	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. Journal of Antimicrobial Chemotherapy, 2013, 68, 726-727.	1.3	42
85	Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Frontiers in Pharmacology, 2013, 4, 156.	1.6	204
86	Pregabalin for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy, 2012, 13, 1527-1533.	0.9	19
87	Pharmacogenetics of pain and analgesia. Clinical Genetics, 2012, 82, 321-330.	1.0	31
88	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Critical Care, 2012, 16, R194.	2.5	233
89	Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LCâ€“MS/MS) for determination of risedronate concentrations in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 881-882, 34-41.	1.2	21
90	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiology, 2012, 12, 29.	0.7	90

#	Article	IF	Citations
91	High-throughput assay for simultaneous quantification of the plasma concentrations of morphine, fentanyl, midazolam and their major metabolites using automated SPE coupled to LCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 903, 126-133.	1.2	51
92	Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. Journal of Critical Care, 2012, 27, 741.e9-741.e18.	1.0	257
93	Synthesis and Biological Evaluation of an Orally Active Glycosylated Endomorphin-1. Journal of Medicinal Chemistry, 2012, 55, 5859-5867.	2.9	72
94	Lipo-Endomorphin-1 Derivatives with Systemic Activity against Neuropathic Pain without Producing Constipation. PLoS ONE, 2012, 7, e41909.	1.1	29
95	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 105-11.	0.0	19
96	Pain, analgesia and genetics. Journal of Pharmacy and Pharmacology, 2011, 63, 1387-1400.	1.2	43
97	Longitudinal Study of Painful Diabetic Neuropathy in the Zucker Diabetic Fatty Rat Model of Type 2 Diabetes: Impaired Basal G-Protein Activity Appears to Underpin Marked Morphine Hyposensitivity at 6 Months. Pain Medicine, 2011, 12, 437-450.	0.9	26
98	Insulin Implants Prevent the Temporal Development of Mechanical Allodynia and Opioid Hyposensitivity for 24-Wks in Streptozotocin (STZ)-Diabetic Wistar Rats. Pain Medicine, 2011, 12, 782-793.	0.9	13
99	PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. British Journal of Cancer, 2011, 104, 635-642.	2.9	154
100	Pregabalin in severe burn injury pain: A double-blind, randomised placebo-controlled trial. Pain, 2011, 152, 1279-1288.	2.0	74
101	Preliminary Study of the Plasma and Cerebrospinal Fluid Concentrations of IL-6 and IL-10 in Patients with Chronic Pain Receiving Intrathecal Opioid Infusions by Chronically Implanted Pump for Pain Management. Pain Medicine, 2010, 11, 550-561.	0.9	29
102	A Randomized, Controlled Trial of Oxycodone Versus Placebo in Patients With PostHerpetic Neuralgia and Painful Diabetic Neuropathy Treated With Pregabalin. Journal of Pain, 2010, 11, 462-471.	0.7	85
103	Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and dynorphin A(2-17) following spinal and supraspinal routes of administration. Pharmacology Biochemistry and Behavior, 2009, 93, 498-505.	1.3	15
104	ANTINOCICEPTION VERSUS SERUM CONCENTRATION RELATIONSHIPS FOLLOWING ACUTE ADMINISTRATION OF INTRAVENOUS MORPHINE IN MALE AND FEMALE SPRAGUEâ€DAWLEY RATS: DIFFERENCES BETWEEN THE TAIL FLICK AND HOT PLATE NOCICEPTIVE TESTS. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 20-28.	0.9	29
105	Ï‡-Conopeptide Pharmacophore Development: Toward a Novel Class of Norepinephrine Transporter Inhibitor (Xen2174) for Pain. Journal of Medicinal Chemistry, 2009, 52, 6991-7002.	2.9	70
106	SEX DIFFERENCES IN THE PHARMACOKINETICS, OXIDATIVE METABOLISM AND ORAL BIOAVAILABILITY OF OXYCODONE IN THE SPRAGUE-DAWLEY RAT. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 295-302.	0.9	46
107	An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy. CNS Drugs, 2008, 22, 417-442.	2.7	97
108	Differences between and combinations of opioids re-visited. Current Opinion in Anaesthesiology, 2008, 21, 596-601.	0.9	34

#	Article	IF	Citations
109	Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain, 2007, 132, 289-300.	2.0	149
110	Studies on neurosteroids XIX. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 188-199.	1.2	45
111	Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatographyâ€“electrospray ionizationâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 848, 264-270.	1.2	22
112	STUDIES WITH KETAMINE AND ALFENTANIL FOLLOWING FREUND'S COMPLETE ADJUVANT-INDUCED INFLAMMATION IN RATS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 414-420.	0.9	5
113	Oxycodoneâ€™s Mechanism of Action and Potency Differences after Spinal and Systemic Routes of Administration. Anesthesiology, 2007, 106, 1063-1064.	1.3	7
114	Simultaneous determination of morphine, oxycodone, morphine-3-glucuronide, and noroxycodone concentrations in rat serum by high performance liquid chromatographyâ€“electrospray ionizationâ€“tandem mass spectrometryâ€ . Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 241-249.	1.2	36
115	Co-administration of oxycodone and morphine and analgesic synergy re-examined. British Journal of Clinical Pharmacology, 2005, 59, 486-487.	1.1	6
116	Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. British Journal of Clinical Pharmacology, 2005, 59, 524-535.	1.1	25
117	Comparison of the Pharmacokinetics of Oxycodone and Noroxycodone in Male Dark Agouti and Sprague–Dawley Rats: Influence of Streptozotocin-Induced Diabetes. Pharmaceutical Research, 2005, 22, 1489-1498.	1.7	22
118	Anti-allodynic efficacy of the Ï‡-conopeptide, Xen2174, in rats with neuropathic pain. Pain, 2005, 118, 112-124.	2.0	78
119	Measurement of intracellular Ca2+ in cultured rat embryonic hippocampal neurons using a fluorescence microplate reader: potential application to biomolecular screening. Journal of Pharmacological and Toxicological Methods, 2004, 49, 81-87.	0.3	21
120	Deletion of guanine nucleotide binding protein Î±z subunit in mice induces a gene dose dependent tolerance to morphine. Neuropharmacology, 2004, 46, 836-846.	2.0	26
121	The Neuroexcitatory Morphine Metabolite, Morphine-3-glucuronide (M3G), is not Neurotoxic in Primary Cultures of either Hippocampal or Cerebellar Granule Neurones. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 197-200.	0.0	3
122	The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung and Circulation, 2003, 12, 44-50.	0.2	173
123	Morphine-3-Glucuronideâ€™s Neuro-Excitatory Effects Are Mediated via Indirect Activation of N-Methyl-d-Aspartic Acid Receptors: Mechanistic Studies in Embryonic Cultured Hippocampal Neurones. Anesthesia and Analgesia, 2003, 97, 494-505.	1.1	61
124	The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain, 2002, 96, 119-127.	2.0	155
125	A simple, low-cost, remote fiber-optic micro volume fluorescence flowcell for capillary flow-injection analysis. Analytical and Bioanalytical Chemistry, 2002, 374, 385-389.	1.9	12
126	Hydromorphone-3-glucuronide. Life Sciences, 2001, 69, 409-420.	2.0	119

#	Article	IF	Citations
127	Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. British Journal of Clinical Pharmacology, 2001, 52, 693-698.	1.1	33
128	Sensory changes during the ovulatory phase of the menstrual cycle in healthy women. European Journal of Pain, 2001, 5, 135-144.	1.4	65
129	Oxycodone has a distinctly different pharmacology from morphine. European Journal of Pain, 2001, 5, 135-136.	1.4	8
130	The role of morphine-6-glucuronide (M6G) in pain control. Pain Reviews, 2001, 8, 171-191.	0.0	6
131	Neuroexcitatory Effects Of Morphine And Hydromorphone: Evidence Implicating The 3-Glucuronide Metabolites. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 524-528.	0.9	255
132	Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain, 2000, 84, 421-428.	2.0	75
133	Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sciences, 1999, 65, 225-236.	2.0	27
134	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. Anesthesia and Analgesia, 1999, 88, 109-116.	1.1	9
135	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. Anesthesia and Analgesia, 1999, 89, 409-415.	1.1	17
136	Cerebrospinal Fluid and Plasma Concentrations of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Patients Before and After Initiation of Intracerebroventricular Morphine for Cancer Pain Management. Anesthesia and Analgesia, 1999, 88, 109-116.	1.1	34
137	Intraarticular and Periarticular Opioid Binding in Inflamed Tissue in Experimental Canine Arthritis. Anesthesia and Analgesia, 1999, 89, 409-415.	1.1	42
138	Solid-phase extraction method with high-performance liquid chromatography and electrochemical detection for the quantitative analysis of oxycodone in human plasma. Biomedical Applications, 1998, 712, 169-175.	1.7	22
139	Investigation of the antinociceptive efficacy and relative potency of extended duration injectable 3-acylmorphine-6-sulfate prodrugs in rats. International Journal of Pharmaceutics, 1998, 163, 191-201.	2.6	9
140	Hydromorphone-3-glucuronide: Biochemical synthesis and preliminary pharmacological evaluation. Life Sciences, 1998, 63, 401-411.	2.0	49
141	Clinical Pharmacology and Adverse Effects. , 1998, , 188-211.		1
142	Improved One-Step Solid-Phase Extraction Method for Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide From Plasma and Quantitation Using High-Performance Liquid Chromatography With Electrochemical Detection. Therapeutic Drug Monitoring, 1998, 20, 215-218.	1.0	8
143	Morphine has a Dual Concentration-dependent Effect on K+-evoked Substance P Release from Rat Peripheral Airways. Pulmonary Pharmacology and Therapeutics, 1997, 10, 215-221.	1.1	14
144	Biochemical synthesis, purification and preliminary pharmacological evaluation of normorphine-3-glucuronide. Life Sciences, 1997, 61, 95-104.	2.0	7

#	Article	IF	Citations
145	The intrinsic antinociceptive effects of oxycodone appear to be Î¹ -opioid receptor mediated. Pain, 1997, 73, 151-157.	2.0	228
146	Quantitative autoradiography of peripheral opioid binding sites in rat lung. European Journal of Pharmacology, 1996, 310, 47-53.	1.7	25
147	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. Anesthesia and Analgesia, 1995, 80, 296-302.	1.1	1
148	Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain. Anesthesia and Analgesia, 1995, 80, 296-302.	1.1	87
149	Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain, 1995, 62, 51-60.	2.0	107
150	Effects of morphine-3-glucuronide and morphine on the K+-evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes. Life Sciences, 1995, 58, 447-454.	2.0	13
151	Characterization of non-conventional opioid binding sites in rat and human lung. European Journal of Pharmacology, 1994, 268, 247-255.	2.7	47
152	Pharmacology of Morphine and Morphineâ€3â€glucuronide at Opioid, Excitatory Amino Acid, GABA and Glycine Binding Sites. Basic and Clinical Pharmacology and Toxicology, 1994, 75, 73-81.	0.0	62
153	Comments on Goucke et al., Pain, 56 (1994) 145â€“149. Pain, 1994, 59, 155-156.	2.0	0
154	The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sciences, 1994, 54, 687-694.	2.0	91
155	The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sciences, 1994, 54, 1229-1236.	2.0	46
156	Quantitation of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Plasma and Cerebrospinal Fluid Using Solid-Phase Extraction and High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring, 1994, 16, 200-208.	1.0	55
157	Determination of the Serum Protein Binding of Oxycodone and Morphine Using Ultrafiltration. Therapeutic Drug Monitoring, 1993, 15, 440-447.	1.0	45
158	Comparative Oxycodone Pharmacokinetics in Humans After Intravenous, Oral, and Rectal Administration. Therapeutic Drug Monitoring, 1992, 14, 479-484.	1.0	75
159	Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical Pharmacology and Therapeutics, 1992, 52, 487-495.	2.3	136
160	Quantitation of Oxycodone in Human Plasma Using High-Performance Liquid Chromatography with Electrochemical Detection. Therapeutic Drug Monitoring, 1991, 13, 126-130.	1.0	27
161	Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clinical Pharmacology and Therapeutics, 1990, 47, 516-524.	2.3	99
162	Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sciences, 1990, 47, 579-585.	2.0	307

#	Article	IF	Citations
163	Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. European Journal of Clinical Pharmacology, 1986, 31, 177-182.	0.8	44
164	Simple and Reliable Determination of Bromazepam in Human Plasma by High-Performance Liquid Chromatography. Analytica Chimica Acta, 1985, 177, 267-271.	2.6	8
165	A Sensitive Liquid Chromatographic Assay for Plasma Aspirin and Salicylate Concentrations After Low Doses of Aspirin. Therapeutic Drug Monitoring, 1985, 7, 216-221.	1.0	26
166	Pharmacokinetics of midazolam in the aged. European Journal of Clinical Pharmacology, 1984, 26, 381-388.	0.8	58
167	Metabolism of propranolol in the human maternal-placental-foetal unit. European Journal of Clinical Pharmacology, 1983, 24, 727-732.	0.8	14
168	Chronic propranolol administration during pregnancy. European Journal of Clinical Pharmacology, 1983, 25, 481-490.	0.8	12
169	Propranolol in Pregnancy Three Year Prospective Study. Clinical and Experimental Hypertension Part B, Hypertension in Pregnancy, 1983, 2, 341-350.	0.2	23
170	Propranolol, Propranolol Glucuronide, and Naphthoxylactic Acid in Breast Milk and Plasma. Therapeutic Drug Monitoring, 1983, 5, 87-94.	1.0	41
171	Novel Source of Ubiquitous Phthalates as Analytical Contaminant. Journal of Pharmaceutical Sciences, 1981, 70, 346-347.	1.6	3
172	The unsteady model. European Journal of Clinical Pharmacology, 1981, 20, 387-398.	0.8	5
173	The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology, 1981, 19, 271-278.	0.8	266
174	Pharmacokinetics of prazepam in man. European Journal of Clinical Pharmacology, 1979, 16, 141-147.	0.8	17